These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

587 related items for PubMed ID: 31089973

  • 1. Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer.
    Tanaka H, Taima K, Itoga M, Ishioka Y, Baba K, Shiratori T, Sakamoto H, Tsuchiya J, Nakagawa H, Hasegawa Y, Yasugahira H, Okudera K, Takanashi S, Tasaka S.
    Med Oncol; 2019 May 14; 36(6):57. PubMed ID: 31089973
    [Abstract] [Full Text] [Related]

  • 2. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
    Lin YT, Chen JS, Liao WY, Ho CC, Hsu CL, Yang CY, Chen KY, Lee JH, Lin ZZ, Shih JY, Yang JC, Yu CJ.
    Int J Cancer; 2019 Jun 01; 144(11):2887-2896. PubMed ID: 30485437
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib.
    Kim Y, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM.
    Cancer Res Treat; 2019 Apr 01; 51(2):502-509. PubMed ID: 29898592
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non-small-cell lung cancer: a multi-institute retrospective study.
    Hung LJ, Hsu PC, Yang CT, Kuo CS, Chang JW, Huang CY, Chang CF, Wu CE.
    Aging (Albany NY); 2024 Jan 08; 16(1):550-567. PubMed ID: 38194721
    [Abstract] [Full Text] [Related]

  • 5. The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
    Jung HA, Park S, Lee SH, Ahn JS, Ahn MJ, Sun JM.
    Cancer Res Treat; 2023 Apr 08; 55(2):479-487. PubMed ID: 36596729
    [Abstract] [Full Text] [Related]

  • 6. Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population.
    Sutandyo N, Hanafi A, Jayusman M.
    Zhongguo Fei Ai Za Zhi; 2019 Sep 20; 22(9):562-567. PubMed ID: 31526459
    [Abstract] [Full Text] [Related]

  • 7. Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.
    Yamaguchi O, Kaira K, Mouri A, Shiono A, Hashimoto K, Miura Y, Nishihara F, Murayama Y, Kobayashi K, Kagamu H.
    Cancer Chemother Pharmacol; 2019 May 20; 83(5):817-825. PubMed ID: 30758646
    [Abstract] [Full Text] [Related]

  • 8. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC, Lim CK, Chang LY, Chen KY, Shih JY, Yu CJ.
    Eur J Cancer; 2019 Sep 20; 119():77-86. PubMed ID: 31425965
    [Abstract] [Full Text] [Related]

  • 9. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
    Chen YH, Chen YF, Chen CY, Shih JY, Yu CJ.
    BMC Cancer; 2019 Oct 26; 19(1):1006. PubMed ID: 31655564
    [Abstract] [Full Text] [Related]

  • 10. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan.
    Chang JW, Huang CY, Fang YF, Chang CF, Yang CT, Kuo CS, Hsu PC, Wu CE.
    Thorac Cancer; 2023 Jan 26; 14(1):12-23. PubMed ID: 36424878
    [Abstract] [Full Text] [Related]

  • 11. From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study).
    Pasello G, Vicario G, Zustovich F, Oniga F, Gori S, Rosetti F, Bonetti A, Favaretto A, Toso S, Redelotti R, Santo A, Bernardi D, Giovanis P, Oliani C, Calvetti L, Gatti C, Palazzolo G, Baretta Z, Bortolami A, Bonanno L, Basso M, Menis J, Corte DD, Frega S, Guarneri V, Conte P, Veneto Oncology Network.
    Oncologist; 2019 Jun 26; 24(6):e318-e326. PubMed ID: 30846513
    [Abstract] [Full Text] [Related]

  • 12. Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients.
    Wu TH, Hsiue EH, Lee JH, Lin CC, Liao WY, Ho CC, Shih JY, Yu CJ, Yang JC.
    Clin Lung Cancer; 2018 May 26; 19(3):e361-e372. PubMed ID: 29477365
    [Abstract] [Full Text] [Related]

  • 13. Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta-analysis of real-world survival outcomes of East Asian patients with advanced non-small cell lung cancer treated with first-line EGFR-TKIs.
    Chang HC, Wang CC, Tseng CC, Huang KT, Chen YM, Chang YP, Lai CH, Fang WF, Lin MC, Chuang HY.
    Thorac Cancer; 2023 Nov 26; 14(32):3208-3216. PubMed ID: 37737541
    [Abstract] [Full Text] [Related]

  • 14. Comparing the effectiveness of different EGFR-TKIs in patients with EGFR mutant non-small-cell lung cancer: A retrospective cohort study in Taiwan.
    Hsieh YY, Fang WT, Lo YW, Chen YH, Chien LN.
    Int J Cancer; 2020 Aug 15; 147(4):1107-1116. PubMed ID: 31854456
    [Abstract] [Full Text] [Related]

  • 15. Clinical analysis of EGFR-positive non-small cell lung cancer patients treated with first-line afatinib: A Nagano Lung Cancer Research Group.
    Sonehara K, Kobayashi T, Tateishi K, Morozumi N, Yoshiike F, Hachiya T, Ono Y, Takasuna K, Agatsuma T, Masubuchi T, Matsuo A, Tanaka H, Morikawa A, Hanaoka M, Koizumi T.
    Thorac Cancer; 2019 May 15; 10(5):1078-1085. PubMed ID: 31006178
    [Abstract] [Full Text] [Related]

  • 16. Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea.
    Choi MK, Ahn JS, Kim YC, Cho BC, Oh IJ, Kim SW, Lee JS, Kim JH, Ahn MJ, Park K.
    Lung Cancer; 2018 May 15; 119():36-41. PubMed ID: 29656750
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and dose of afatinib in patients with non-small cell lung cancer after failure of prior gefitinib or erlotinib treatment.
    Choi H, Lee JK, Oh HJ, Kim MS, Kho BG, Park CK, Oh IJ, Kim YC.
    Thorac Cancer; 2021 May 15; 12(10):1598-1604. PubMed ID: 33811467
    [Abstract] [Full Text] [Related]

  • 18. Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01).
    Uryu K, Imamura Y, Shimoyama R, Mase T, Fujimura Y, Hayashi M, Ohtaki M, Otani K, Hibino M, Horiuchi S, Fukui T, Fukai R, Chihara Y, Iwase A, Yamada N, Tamura Y, Harada H, Shinozaki N, Tsuya A, Fukuoka M, Minami H.
    Jpn J Clin Oncol; 2024 Mar 09; 54(3):319-328. PubMed ID: 37997468
    [Abstract] [Full Text] [Related]

  • 19. Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting.
    Kwok WC, Ho JCM, Tam TCC, Ip MSM, Lam DCL.
    Thorac Cancer; 2022 Jul 09; 13(14):2057-2063. PubMed ID: 35668712
    [Abstract] [Full Text] [Related]

  • 20. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K, Hata A, Takeshita J, Okuda C, Kaji R, Masago K, Fujita S, Katakami N.
    Cancer Chemother Pharmacol; 2015 Oct 09; 76(4):835-41. PubMed ID: 26349474
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.